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INTRODUCTION
With the considerable increase in the life 
expectancy of HIV-infected patients in the era of 
high-activity antiretroviral therapy (ART), some of 
the consequences of prolonged viral infection and that 
treatment have been seen. The metabolic consequences 
occurring within this context are explored in 
several publications in the literature, especially the 
lipodystrophy syndrome. Currently, the increasing 
observation of osteoarticular changes in these patients 
is the subject of more detailed study, with the aim of 
detecting their possible causes and determining the 
most appropriate therapeutic approach.
Among the complex metabolic changes in chronic 
HIV infection and its treatment, there is a decrease of 
bone mineralization in a high proportion of patients 
resulting from various factors present in the host itself, 
in the virus, and in the antiretroviral drugs (ARV). 
Bone is continuously remodeled by the synchroni-
zation of its formation and resorption, which can be 
deregulated during HIV infection. Bone mineraliza-
tion decreases, causing osteopenia, which can result 
in osteoporosis.
The osteoarticular changes most frequently repor-
ted in patients infected for a long period with HIV and 
using ART are osteopenia/osteoporosis, osteonecro-
sis, carpal tunnel syndrome, and adhesive capsulitis 
of the shoulders.
Osteopenia/osteoporosis
According to the World Health Organization, the 
definitions of osteopenia and osteoporosis are based 
on bone densitometry results(1). Osteoporosis is defi-
ned as when this ratio is less than 2 times the standard 
deviation, and osteopenia when the result is between 
-1 and -2 times the standard deviation(2). Osteoporosis 
can be considered severe when, in addition to this 
criterion, the patient has a fracture (Figure 1).
Several studies have shown a high prevalence of 
these abnormalities in patients infected with HIV, 
according to these criteria(1-4,6-11). Multiple factors 
have been reported as causes of osteopenia, including 
the direct effects of the virus on osteogenic cells; 
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There have been studies regarding the influence 
of antiretroviral therapy that show an increased risk 
when using protease inhibitors (PI), since indinavir 
is known to inhibit bone formation and ritonavir is 
known to inhibit osteoclast differentiation and func-
tion(1,6,7,9-11). Recent reports on reverse transcriptase 
inhibitors have linked tenofovir to the occurrence of 
osteomalacia and Fanconi syndrome(12). Still other 
factors may contribute to accelerated bone loss, such 
as nutritional deficiency, low serum calcium levels, 
immobilization, hypogonadism, hyperthyroidism, 
hyperparathyroidism, renal failure, use of opioids 
or heroin, use of corticosteroids, postmenopause in 
women, and alcohol consumption greater than 16g/
day(1,8) (Figures 3 and 4).
persistent activation of proinflammatory cytokines, 
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the metabolism of vitamin D, with a deficiency 
in 1,25-dihydroxyvitamin-D; and the participation 
of mitochondrial abnormalities related to lactic 
acidemia and the development of opportunistic 
infections(4,5) (Figure 2).
Normal bone
Mineral density (>-1.0)
Osteopenia (-1.0 to -2.5)
Osteoporosis (<-2.5)
0
-1.0
-2.5
Figure 1 – Graphical representation of the normal ranges and 
changes in bone mineral density based on standard deviation 
from the general population.
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Figure 2 – Biochemical markers of bone metabolism.
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Figure 3 – Meta-analysis: risk of osteoporosis in HIV patients 
and control population.
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Figure 4 – Algorithm: investigation and prevention of complica-
tions of decreased bone mineral density.
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The main form of osteoporosis treatment is pre-
vention, conducted by encouraging physical activity 
and proper nutrition in the first three decades of life 
in order to reach maximum bone mass formation.
Calcium intake and supplementary vitamin D 
should be part of any therapeutic regimen for osteo-
porosis. In postmenopausal women, hormone replace-
ment therapy is an important method of prevention of 
osteoporosis. As for drug therapy, there are basically 
two classes of medications: bone antiresorptive agents 
and bone formation-stimulating agents.
Osteonecrosis
The occurrence of osteonecrosis in patients with 
HIV has been reported since 1990, with incidences 
that are progressively increasing and higher than the 
general population(7,8). The annual incidence of symp-
tomatic osteonecrosis in the general population is es-
timated between 0.010 and 0.135%(13).
Recent studies using magnetic resonance imaging 
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(MRI) to detect osteonecrosis in patients with 
HIV have estimated its incidence to be approxi-
mately 4%. The incidence of bilaterality ranges 
from 35 to 80%(13).
In the general population, there some known risk 
factors and conditions associated with the develop-
ment of osteonecrosis, such as the use of systemic 
corticosteroids, alcoholism, hyperlipidemia, sickle cell 
anemia, coagulopathies, Gaucher’s disease, systemic 
lupus erythematosus, rheumatoid arthritis, hyperuri-
cemia and gout, radiation therapy, obesity, pancrea-
titis, fracture sequelae, chemotherapy, vasculitis, and 
smoking. Besides these factors, in the development of 
osteonecrosis in patients infected with HIV, we also 
have dyslipidemia, the use of megestrol acetate and 
steroids, testosterone replacement, as well as the forms 
of vasculitis that predispose the patient to intraosseous 
thrombosis by the presence of anticardiolipin anti-
bodies and by a deficiency of S protein. Moreover, 
the antiretroviral therapy itself may be related to the 
increasing development of osteonecrosis(7,8,13).
For the diagnosis of osteonecrosis, clinical signs 
should be observed, such as the presence of joint 
pain and limitations in the range of motion. The 
most frequently involved joints are the hips, unila-
terally or bilaterally, the knees, ankles, elbows, and 
shoulders(14,15).
It should be noted that the interval between ra-
diological changes and clinical symptoms can be 
long, ranging from three to eight years. Simple ra-
diographs of the joint have low diagnostic sensitivity 
early in the disease. The radiological findings fre-
quently indicating osteonecrosis include cystic scle-
rosis, subchondral radiolucency, bone collapse, and 
degenerative joint changes. Computed tomography 
without contrast adds little information to ordinary 
radiographs. MRI has 99% sensitivity and speci-
ficity for diagnosis from the earliest phase. Bone 
scintigraphy can be used to determine its stage and 
in the search for hidden asymptomatic foci, although 
it is not very specific(14,15).
Treatment varies with the stage of the disease. In 
patients with HIV, it is important to exclude or control 
other risk factors that are not part of the disease itself 
or the antiretroviral drug. In oligosymptomatic indivi-
duals, treatment may be based on the use of analgesics 
and non-hormonal anti-inflammatory drugs(6).
Decompression procedures can be used in the area 
of necrosis in the early stages, with or without free 
or pedicled cortico-spongious grafts. With disease 
progression, when changes in articular congruence 
begin, procedures such as osteotomies, unicompart-
mental arthroplasty or hemiarthroplasties may be in-
dicated, and in more advanced cases, the solution is 
total arthroplasty(14).
Carpal tunnel syndrome
The incidence in the general population is around 
3.8% with clinical examination and, when electroneu-
romyography is used, it is 2.7%. In the HIV-positive 
population, the incidence has remained very close to 
that of the general population(16,17).
This syndrome has been associated with the use of 
ART, especially protease inhibitors, and would result 
from known metabolic disorders and as myxedema-
tous material is deposited in the carpal tunnel, with 
consequent nerve compression. Other factors such as 
professional activities, hypothyroidism, hyperglyce-
mia, rheumatoid arthritis, obesity, and various meta-
bolic disorders are associated with the development of 
this syndrome in patients with HIV/AIDS. Therefore, 
the direct correlation with the presence of HIV and 
antiretroviral therapy is still questionable(16,17).
Treatment is based on the stage of the compression 
syndrome. In the mild stage, treatment is conservative, 
with the use of nocturnal splints and the use of anti-
inflammatory medications(18). In the moderate and 
severe stages, surgical treatment is indicated. This can 
be performed conventionally or endoscopically(18). In 
both procedures, the median nerve is decompressed 
through the opening of the flexor retinaculum.
Adhesive capsulitis
Adhesive capsulitis has been linked to HIV patients 
receiving an ART regimen with PIs(19). The reported 
cases are limited to shoulder involvement, suggesting 
that other sites are rare(19,20). The condition’s charac-
teristic symptoms include progressive unilateral or 
bilateral pain in the shoulders, with restricted active 
and passive ranges of motion. Classically, the onset 
of symptoms is insidious, occurring about 12 to 14 
months after initiation of the use of PIs(19). Simple 
radiographs may show bone rarefaction caused by 
disuse, however, magnetic resonance arthrography is 
the examination of choice for diagnosis. Symptoms 
tend to regress spontaneously after a period of six to 
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24 months with the institution of adequate treatment 
and interruption of ART(19,20).
The treatment of adhesive capsulitis depends on 
its time course and the severity of adhesions. In mil-
der cases, conservative treatment with analgesics, 
anti-inflammatory drugs, and physical therapy is the 
most suitable(19,21). In the most severe cases, which are 
unresponsive to conservative treatment, arthroscopic 
treatment is the most suitable, followed by early mo-
bilization. We have avoided the indication of manipu-
lation alone due to the higher incidence of proximal 
humerus fractures and its more painful postoperative 
period, which makes early mobilization difficult(21).
DISCUSSION
Given the prevalence and importance of osteoar-
ticular changes, in March 2006 the IOT began caring 
for HIV/AIDS patients with orthopedic complaints 
who were referred from two referral centers for the 
treatment of patients infected with HIV.
From March 2006 to March 2008, of the 206 
patients evaluated, 83 were enrolled in the clinic, 
with a total of 614 visits between initial consulta-
tions and returns.
The patients studied had prolonged HIV infec-
tion, with an average of 114 months since diagnosis. 
They also had prolonged exposure to ART, with a 
mean of 96 months of use. Among the most widely 
used drugs were lamivudine, zidovudine, and nel-
finavir. There was a history of PI use in 72% of the 
sample (Figure 5).
At the time of evaluation, only 8% of patients had 
CD4 counts below 200 cells/mm3 and 74% had an 
undetectable viral load.
The most prevalent orthopedic change in this 
population was osteonecrosis, with an incidence of 
12%. The hip joint was the most affected, with fin-
dings of bilaterality in all cases. One hundred per 
cent bilaterality is easily explained for all cases by 
the origin being secondary, which raises this index 
(Figure 6 and Table 1).
The chief patient complaint initially consisted of 
only hip pain with limitation of motion and limping 
during evolution, following the classical clinical pic-
ture of the disease.
All patients diagnosed with osteonecrosis were in 
advanced stages of the disease.
This fact may indicate a disease with a more 
Figure 5 – Distribution of ART among HIV-infected patients mo-
nitored at the IOT outpatient clinic. 
Figure 6 – Distribution by topography of orthopedic injuries in 
HIV-infected patients monitored at the IOT outpatient clinic. 
Distribution by topography of orthopedic injuries
30% Spine
2% Elbow 
21% Knee
9% Hand/Wrist
2% Lower limbs
18% Shoulder
7% Foot
11% Hip
Table 1 – Osteoarticular changes. 
Upper limbs Lower limbs Degenerative Axial skeleton
Osteonecrosis of the 
humeral head
Osteonecrosis of the 
femoral head
Tendinopathies Mechanical back 
pain
Carpal tunnel 
syndrome
Osteonecrosis of the 
femoral condyle
Muscular injuries Vertebral body 
collapse
Adhesive shoulder 
capsulitis
Metatarsalgia
Femoropatelar 
syndrome
Ritonavir alone
Ritonavir
Atazanavir
Lopinavir
Nelfinavir
Fosamprenavir
Amprenavir
Indinavir
Saquinavir
Nevirapine
Efavirenz
Tenofovir
Abacavir
Lamivudine
Stavudine
Zalcitabine
Didanosine
Zidovudine
ART Distribution
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CONCLUSION
Osteoarticular complications show a significant 
prevalence in the population living with HIV receiving 
high-activity antiretroviral therapy, with a pattern 
of clinical presentation, natural disease course, and 
response to therapy that is different from those of the 
general population.
aggressive course or a longer delay in diagnosis, 
probably related to the abundant clinical manifestations 
of this population and little appreciation for secondary 
complaints. In addition, we observed a trend of more 
rapid clinical disease progression in this study, with 
more intense pain and a pattern of response to non-
surgical treatment that is less favorable than that of 
the general population.
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